scispace - formally typeset
J

Jon A. van Heerden

Researcher at Mayo Clinic

Publications -  180
Citations -  15845

Jon A. van Heerden is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Primary hyperparathyroidism & Hyperparathyroidism. The author has an hindex of 72, co-authored 179 publications receiving 15196 citations. Previous affiliations of Jon A. van Heerden include University of Toronto & University of Rochester.

Papers
More filters
Journal ArticleDOI

Follicular Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome

TL;DR: The overall mortality observed at 30 years was only 3% above that expected, and death from thyroid cancer was highly associated with the following factors: age more than 50 years, male sex, tumor size, tumor grade, initial extent of disease, and absence of Hashimoto's disease.
Journal ArticleDOI

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

TL;DR: It is uncertain whether more extensive primary surgery and increasing use of radioiodine remnant ablation for papillary thyroid carcinoma (PTC) have resulted in improved rates of cause-specific mortality (CSM) and tumor recurrence (TR).
Journal ArticleDOI

Role for adrenal venous sampling in primary aldosteronism

TL;DR: AVS is an essential diagnostic step in most patients to distinguish between unilateral and bilateral adrenal aldosterone hypersecretion, and on the basis of CT findings alone, 42 patients would have been incorrectly excluded as candidates for adrenalectomy, and 48 patients might have had unnecessary or inappropriate Adrenalectomy.
Journal ArticleDOI

Benign Paragangliomas: Clinical Presentation and Treatment Outcomes in 236 Patients

TL;DR: Most paragangliomas are nonhypersecretory and located in the head and neck region, and metaiodobenzylguanidine was the least sensitive imaging study.
Journal ArticleDOI

Anaplastic thyroid carcinoma: A 50-year experience at a single institution

TL;DR: Multimodal therapy, including operation, chemotherapy, and radiotherapy, did not improve survival and the outlook for patients with ATC remains grim.